Navigation Links
Inventive combination of research approaches identifies new target for treating leukemia
Date:10/5/2009

New research integrates sophisticated interdisciplinary approaches to solve a molecular mystery that may lead to alternative therapeutic strategies for acute myeloid leukemia (AML). The study, published by Cell Press in the October issue of the journal Cancer Cell, identifies a previously unrecognized AML target that responds well to pharmacological inhibition and may be an excellent candidate for use in future clinical trials.

AML is a type of blood cancer that disrupts normal blood cell production. "Long term survival for patients with AML remains poor despite dose-intensive chemotherapy regimens," explains senior study author, Dr. Kimberly Stegmaier from Dana-Farber Cancer Institute, Broad Institute of Harvard and MIT, and Children's Hospital Boston. "For older adults, long-term survival is dismal, and many older patients are unable to tolerate standard cytotoxic therapy." Unfortunately, identification of new treatment strategies has proven difficult as many potential targets are proteins that do not respond well to standard pharmacological methods.

Another challenge has been to unravel the molecular mechanisms associated with compounds that inhibit or reverse AML progression. Target identification is necessary for optimization of drug treatment. Dr. Stegmaier and colleagues had previously demonstrated that epidermal growth factor receptor (EGFR) inhibitors exhibited anti-AML activity. However, this finding was somewhat puzzling as EGFR is not expressed in AML. The researchers made use of sophisticated cross-disciplinary approaches to study gene expression (genomics) and protein structure and function (proteomics) to elucidate the molecular basis for the effect of EGFR inhibitors in AML.

Spleen tyrosine kinase (Syk) was identified as a target in AML. Syk is expressed in blood cells and is critical for proper blood cell differentiation. Recent research has implicated Syk in blood cancers, specifically lymphomas and leukemias. Genetic and pharmacological inactivation of Syk resulted in anti-AML activity in AML cell lines, primary patient samples and animal models of AML. Importantly, there are Syk inhibitors currently being tested in clinical trials.

These results identify Syk as a promising therapeutic target for treatment of AML. "With an orally available, well-tolerated Syk inhibitor currently in clinical development for other indications, our results should have immediate relevance for clinical testing of Syk inhibition in patients with AML," say Dr. Stegmaier. "Our study also validates the feasibility of integrating genetic and proteomic approaches to identify small molecules and their mechanisms of action."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Modern Health Care Economics is Driving Inventiveness in Delivery of Cancer Surgery and Management of Risk
2. Combination of PET/CT tests can expedite diagnosis of lung cancer in a fast-track setting
3. Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
4. Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
5. More Sleep & Less Sex - A Losing Combination
6. Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
7. Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice
8. Mega-Catch™ 3000 Combination Lure Attracts Asian Tiger Mosquitoes (Aedes Albopictus)
9. Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination
10. Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study
11. BBV Vietnam S.E.A. Acquisition Corp. Announces Signing of Letter of Intent for Business Combination with Migami, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, China – ... ... (PRWEB) January 18, 2017 -- Global public health organization ... reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking Water ... drinking water treatment units. This certification verifies that MicroCeramics’ NanoNose ...
(Date:1/18/2017)... ... ... The V Foundation for Cancer Research, a top-rated cancer research charity, announced ... to compete in the Boston Marathon on April 17. From first-time participants to ... marathon to join Team V and support the Foundation’s mission to declare victory over ...
(Date:1/18/2017)... ... 2017 , ... PrideStaff, a national, franchised staffing organization ... Turner Pizarro, was recently featured on Fox Business Network's Worldwide Business with kathy ... leaders from across the globe, provides viewers an opportunity to find solutions to ...
(Date:1/18/2017)... ... January 18, 2017 , ... Park Agencies Insurance ... services to families and business owners in the greater Kansas City area, is ... developmental disabilities. , The Lakemary Center is a comprehensive educational resource center that ...
(Date:1/18/2017)... ... January 18, 2017 , ... Dr. Farhan Qureshi is an esteemed dentist ... His modern dental practice has two convenient office locations in Alexandria and Arlington, Virginia. ... Dentist for the Alexandria area. This award confirms the fact that Dr. Qureshi’s ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , January 18, 2017 According to a new report ... Application: Global Opportunity Analysis and Industry Forecast, 2014 - 2022," the global polyphenol ... $1,127 million by 2022, growing at a CAGR of 8.26% from 2016 to ... of revenue. Continue Reading ... ...
(Date:1/18/2017)... GREENWOOD VILLAGE, Colo. , Jan. 18, 2017 /PRNewswire/ ... an independent chain of pharmacies based in ... Safe Rx™ Locking Prescription Vials (LPVs) in selected Good Day ... abuse now have a cost-effective alternative for secure storage," ... Safe Rx.  "For less than the price of a ...
(Date:1/18/2017)... , Jan. 18, 2017   Seno Medical ... of diagnosing breast cancer through the development of an ... Steve Miller as SVP of Engineering. Mr. ... Realization at FUJIFILM SonoSite, with headquarters in ... majority of his 30-year career to the development of ...
Breaking Medicine Technology: